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Abstract Objective: Physicians frequently deviate from
guidelines that promote prudent use of antimicrobials. We
explored to what extent patient and disease characteristics
were associated with compliance with guideline recom-
mendations for three common infections. Methods: In a
1-year prospective observational study, 1,125 antimicro-
bial prescriptions were analysed for compliance with uni-
versity hospital guidelines. Results: Compliance varied
significantly between and within the groups of infections
studied. Compliance was much higher for lower respira-
tory tract infections (LRTIs; 79%) than for sepsis (53%)
and urinary tract infections (UTIs; 40%). Only predispos-
ing illnesses and active malignancies were associated with
more compliant prescribing, whereas alcohol/ intravenous
drug abuse and serum creatinine levels >130 μmol/l were
associated with less compliant prescribing. Availability of
culture results had no impact on compliance with guide-
lines for sepsis but was associated with more compliance
in UTIs and less in LRTIs. Narrowing initial broad-spec-
trum antimicrobial therapy to cultured pathogens was sel-
dom practised. Most noncompliant prescribing concerned
a too broad spectrum of activity when compared with
guideline-recommended therapy. Conclusion: Patient char-
acteristics had only a limited impact on compliant pre-
scribing for a variety of reasons. Physicians seemed to
practise defensive prescribing behaviour, favouring treat-
ment success in current patients over loss of effectiveness
due to resistance in future patients.
Keywords Guidelines . Antibiotic policy . Compliance .
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Introduction
Targeting inappropriate antimicrobial use is an important
feature of current infection control in hospital care [1].
Antimicrobialtreatmentguidelineshavebeendevelopedthat
stronglypromoteprudentantimicrobialprescribing[2–5].At
the hospitallevel,guidelinesare developed incorporatingthe
results of local bacterial resistance patterns. After in vitro
culture and test results are available (herein referred to as
culture-driven therapy), guidelines recommend that therapy
should then be guided by the pathogen’s susceptibility
patterntoantimicrobials[6,7].Theypromoteprescribingthe
narrowest-spectrum drug that adequately covers the isolated
pathogen and that reaches the target site. In culture-driven
therapy, patient characteristics are of little importance
because antimicrobials should simply be chosen by their
ability to eradicate the isolated pathogen.
Unfortunately, physicians often do not comply with guide-
line recommendations [8], nor does availability of culture re-
sultsautomaticallyleadtoadjustmentofantimicrobialtherapy
towards the preferred drug [9, 10]. Many interventions to
improve the use of guidelines have been employed, some
successfully [11, 12], but there is still room for improvement
[13, 14]. It has been suggested that noncompliance may be
driven by the guidelines’ inability to cover all encountered
clinical conditions [15]. This implies that guideline compli-
ance may be limited to a certain ceiling that depends on
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To date, little attention has been given to the impact of
patient and disease characteristics on compliance, although
there are indications that compliance with guidelines varies
for different infectious diseases, such as skin and soft tissue
infection,sepsis,andurinarytract infection(UTIs) [8].Also,
in primary health care, guidelines are more successful in
some therapeutic areas than in others [16]. Information on
the relevance of patient and disease characteristics helps to
increaseourunderstandingofnoncompliancewithguideline
recommendations and to target interventions to improve
prescribing. Additionally, the main study findingshave been
used successfully as feedback material to strengthen guide-
line use in our university hospital [17].
In this study we explored to what extent patient and
disease characteristics were associated with compliance
with guideline recommendations for three commonly
encountered infections. Second, we evaluated the effec-
tiveness and safety of prescriptions that were not in line
with the guidelines’ recommendations.
Methods
Study design
We performed a prospective observational study of
physicians’ antimicrobial prescribing behaviour. Patient
and disease characteristics were collected for all prescrip-
tions of an antimicrobial agent. We then compared
prescribed therapy with guideline recommendations. In
cases of culture-driven therapy, a division was made
between initial antimicrobial prescriptions to therapy-naïve
patients and follow-up prescriptions, that is, those preceded
by earlier empiric or culture-driven antimicrobial therapy
for that particular infection episode.
Study setting and sample
Population The study covered a 1-year period (February
2001–February 2002) and was conducted in the depart-
ments of general internal medicine, including haematol-
ogy, gastroenterology, nephrology, and pulmonology, and
in the intensive care unit of the University Medical Centre
Groningen, the Netherlands (Table 1). Patients were
included in the study when they were prescribed an
antimicrobial agent to treat one of the three most prevalent
infectious diseases: sepsis, UTI, or lower respiratory tract
infection (LRTI). Antimicrobials prescribed for these
infections included systemic antibiotics and antimycotics
(ATC J01, J02, J04) [18].
Setting In the hospital, a hard-copy antimicrobial guideline
published in 1999 was available but had not been actively
implemented. Routine clinical microbiology support was
available upon request; systematic feedback of culture
results was offered only for patients with positive blood-
stream infections. There was no routine involvement of
pharmacy staff in antimicrobial prescribing, and there
were no ongoing activities that addressed antimicrobial
policies. Therapeutic drug monitoring facilities were
offered only on request.
Guideline The local hospital guidelines give general
recommendations for good clinical practice of infectious
diseases (Appendix)[ 19]. They recommend taking timely
culture samples, checking results, and adapting (stopping,
changing, or continuing) antimicrobial therapy when
appropriate. In separate chapters, they cover evidence-
based specific antimicrobial therapy for a wide range of
infections based on national and international guidelines
and adapted when necessary to local antimicrobial resis-
tance patterns. The guidelines are composed by a working
group of professionals from different relevant specialties
in the hospital.
Data collection
Patient, disease, and prescribing data were extracted from
paper medical charts. Bacterial culture and sensitivity test
results and clinical laboratory values were extracted from
the hospital’s electronic information system.
Outcome measures
Prescriptions were compared with guideline recommenda-
tions for specific indications or cultured pathogens by an
independent pharmacist observer. All prescriptions were
assessed individually, and previous, concurrent, or com-
bined antimicrobial therapy was taken into account as well
as the availability of in vitro bacterial test and culture
results. In a pilot study, the reliability of this assessment
method was proven to be good (overall kappa 0.72) [20]. In
cases of culture-driven therapy, in vitro bacterial culture
and sensitivity test results overruled guideline recommen-
dations when isolated pathogens were insensitive to
guideline-recommended agents. Noncompliant prescribed
antimicrobials were compared with guideline-recom-
mended drugs on three criteria relevant for antimicrobial
Table 1 Description of case characteristics (UTI urinary tract
infection, LRTI lower respiratory tract infection)
Sepsis UTI LRTI
Prescriptions N=308 N=191 N=626
Male 179 (58%) 87 (45%) 375 (60%)
Mean age in years 59 (SD 18) 60 (SD 18) 64 (SD 17)
Infection the reason
for admission
164 (53%) 76 (40%) 494 (79%)
Length of stay in days
a 22 (11–40) 23 (12–41) 18 (10–34)
Deaths 62 (20%) 15 (8%) 89 (14%)
Patients 120 133 314
aMedian and interquartile range
298therapy: safety, efficacy, and spectrum of covered patho-
gens. To this purpose, the expert classified prescribed
antimicrobials as having a safety profile better than, similar
to, or poorer than the guideline-recommended agents.
Similarly, for the efficacy criterion, agents were considered
less effective when they did not covering the expected or
cultured pathogens or when they were less able to penetrate
the infection site. The bacterial spectrum was considered
too narrow when cultured or expected pathogens were
inadequately covered. Therapy was considered too broad
when, for a specific indication, more nonpathogenic
bacteria were affected than were affected by guideline-
recommended agents.
Patient and disease characteristics
The following determinants were included:
1. Patient characteristics included age and comorbid dis-
eases known to have an impact on the clinical outcome of
the infections studied, such as active malignancy, cere-
brovascular accident, and congestive heart failure [7].
Immunosuppressive therapy, urinary catheter in situ, and
predisposing illnesses (defined as surgery, trauma, or
solid organ transplant prior to initiation of antimicrobial
therapy) were considered relevant comorbidities as well
[21].
2. Disease severity was measured by a number of proxies,
including fever (>38.5°C) and significantly elevated
levels of inflammation parameters (C-reactive protein
>100 mg/l and leukocyte count <4 or >12*10
9/l).
Proxies for a more severely ill patient were an
increased length of stay (longer than the 11-day
average at the department of internal medicine) and
patient death during hospital stay. Proxies for renal or
liver disorder were serum creatinine levels >130 μmol/
l and elevated liver enzymes (transaminases AST
>60 U/l and ALT >80 U/l). Disease severity proxies
were considered to be clinically relevant if levels were
outside the stipulated range in the 3 days prior to
initiating the antimicrobial prescription and, for fever,
for 24 h prior to prescribing. Validated disease severity
score indices, such as the pneumonia severity index
(PSI) or APACHE [21, 22], were not routinely used in
all wards and were therefore not used.
Analyses
The analysis was performed at the prescription level,
implying that more than one prescription per patient could
be included. For sepsis, UTI, and LRTI, levels of
compliance with specific guideline recommendations
were analysed, considering empiric versus culture-driven
therapy, aetiology, and isolated pathogens. Descriptive
statistics (absolute number of prescriptions and percent-
ages), chi-squares (p-values), and odds ratios (OR) with
95% confidence intervals (95% CI) were calculated. The
effect of patient and disease characteristics were assessed
with a multivariate logistic regression model, including
those characteristics that had a p-value <0.25 in the
univariate analysis.
Results
Characteristics
Eleven hundred and twenty-five antimicrobials were
prescribed to 120 patients with sepsis, 133 patients with
UTI, and 314 patients with LRTI (Table 1). The mean
patient age was 60 years. In case of sepsis and UTI, roughly
half of the antibiotics were prescribed to patients for
nosocomial infections. In cases of LRTI, the majority
(79%) of prescriptions were for community-acquired
infections. Duration of hospital stay was relatively long,
which is understandable in view of the patients included,
such as solid organ transplant and haematology patients.
The majority of UTI patients were female, whereas more
male patients were treated for sepsis and LRTI.
Compliance with guideline recommendations
In 164/308 (53%) prescriptions for sepsis, 76/191 (40%)
for UTI, and 494/626 (79%) for LRTI (p<0.001), a
guideline-recommended antimicrobial agent was used.
When each group of infections was looked at separately
in more detail, guidelines were followed to a different
extent for various clinical problems (Table 2). Treatment
complied poorly with guideline recommendations for
proven Enterobacteriaceae infections in patients with
sepsis. The guidelines recommended tobramycin as first-
line treatment, but that recommendation was followed in
only 20% of the prescriptions. Empiric therapy was
generally poorly compliant for lower UTI, in which the
recommended, mainly narrow-spectrum antibiotics were
not used. The broad-spectrum ciprofloxacin was used in
almost half of the prescriptions for UTI (data not shown),
though it was only recommended in UTI as second-line
treatment for pyelonephritis and prostatitis. Co-amoxiclav
was preferred for treating feverish patients with UTI and a
catheter in situ, instead of the guideline-recommended
combination of amoxicillin and tobramycin.
For LRTI, compliance with guideline recommendations
was by far the best. Notably, for empiric therapy of
hospital-acquired pneumonia (HAP), community-acquired
pneumonia (CAP), or acute bronchitis, the guideline
recommended the same broad-spectrum agent, co-amox-
iclav, which was prescribed in 45% of all LRTI cases.
However, in culture-driven therapy of LRTI, differences in
prescribing compliance were observed (p=0.002). When
treating streptococci (50%) and Staphylococcus aureus
(43%) infections, physicians followed guideline recom-
mendations less than when other pathogens were cultured
(58–87%).
299Compliance with guideline recommendations
between departments
Compliance with guideline recommendations did not
differ between departments (Fig. 1). UTI compliance was
compared only between the departments of general internal
medicine and nephrology because too few prescriptions for
comparison were prescribed in the other departments.
Compliance with guideline recommendations
and availability of in vitro culture test results
Availability of culture results had no impact on compliance
in case of sepsis, but was associated with more compliance
in UTI and less compliance in LRTI (Table 3). No
significant differences in compliance in culture-driven
therapy were observed for prescriptions to patients who
were pretreated (follow-up) with an antimicrobial agent or
to those who were therapy-naïve (initial).
Table 2 Compliance with guideline recommendations for infections, considering aetiology or isolated pathogen (UTI urinary tract
infection, LRTI lower respiratory tract infection, CAP community-acquired pneumonia, HAP hospital-acquired pneumonia, CNS coagulase-
negative staphylococci)
Sepsis UTI LRTI
Empiric therapy
Unknown origin 20 (65%) Lower UTI CAP 215 (82%)
Lungs 38 (45%) -Uncomplicated 13 (39%) HAP 78 (83%)
Urinary tract 69 (41%) -Complicated 52 (12%) Acute bronchitis 80 (85%)
Skin, bone, joints 9 (89%) (Male/catheter) Cystic fibrosis 47 (94%)
Abdomen 30 (70%) Pyelonephritis/epididymitis 7 (71%) Tuberculosis 2 (100%)
p=0.006
a p<0.001 p=0.38
Culture-driven therapy
Enterobacteriaceae 35 (20%) Enterobacteriaceae 65 (40%) Mixed infections 51 (80%)
Mixed infection 25 (56%) (Especially E. coli) Pseudomonas 31 (87%)
S. aureus 21 (86%) Mixed infections 21 (52%) S. aureus 28 (43%)
Streptococci 16 (50%) Enterococci 15 (73%) Streptococci 24 (50%)
CNS 15 (60%) Other 18 (67%) Enterobacteriaceae 20 (65%)
Fungal infections
b 10 (100%) Fungal infections
b 17 (71%)
Other 20 (55%) Other 33 (64%)
p<0.001 p=0.05 p=0.002
ap-values are based on chi-square calculations of levels of compliance with guidelines within specific infection groups, considering whether
therapy was empiric or culture-driven
bCandida, Aspergillus, etc
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Fig. 1 Compliant prescriptions (black bars) and noncompliant
prescriptions (grey bars) across different departments. P-values for
differences in level of compliance between departments are based on
chi-square tests. Guideline compliance is similar for the three
infections across the different subdepartments. For urinary tract
infections (UTI), only general internal medicine (INT) and nephrol-
ogy (NE) departments are compared because the other departments
had too few prescriptions to allow for a reliable comparison. (HEM
haematology, GE gastroenterology, ICU intensive care unit, PUL
pulmonology)
300Patient and disease characteristics and compliance
Empiric antimicrobial therapy was more often in line with
guideline recommendations for septic patients with pre-
disposing illnesses (trauma, surgery, solid organ transplant)
and LRTI patients with active malignancy. In cases of
alcohol/intravenous drug abuse, empiric therapy for sepsis
and culture-driven therapy for LRTI were less compliant
(Table 4). Increased serum creatinine levels (>130 μmol/l)
were associated with less compliant culture-driven pre-
Table 4 The effect of age, co-
morbidity, and disease severity
on antimicrobial drug choice
(UTI urinary tract infection,
LRTI lower respiratory tract in-
fection, CVA cerebrovascular
accident)
Patient/disease characteristics
included in the univariate anal-
ysis: age, active malignancy,
CVA, congestive heart failure,
immunosuppressive therapy,
urinary catheter in situ, predis-
posing illnesses (defined as sur-
gery, trauma, or solid organ
transplant prior to initiation of
antimicrobial therapy). Disease-
severity characteristics included
in the univariate analysis: fever
(>38.5°C), C-reactive protein
>100 mg/l, leukocyte-count <4
or >12*10
9/l, length of stay >11
days, death during hospital stay,
serum creatinine levels
>130 μmol/l, AST >60 U/l,
ALT >80 U/l. Disease severity
proxies were considered to be
clinically relevant if levels were
outside the stipulated range up
to 3 days prior to initiating the
antimicrobial prescription and,
for fever, for 24 h prior to
prescribing
Determinants N (% compliant) Multivariate odds ratio
(95% CI), p-value
Sepsis
Empiric (n=166) Predisposing illness 37 (70%) 2.99 (1.27–7.05), 0.01
Alcohol/ intravenous drug abuse 6 (17%) 0.07 (0.01–0.79), 0.03
Immunosuppressive
medication
46 (44%) 0.49 (0.23–1.03), 0.06
ALT >60 U/l 45 (62%) 2.03 (0.95–4.32), 0.07
Length of stay >11 days 109 (57%) 1.78 (0.88–3.58), 0.11
Culture-driven
(n=142)
Active malignancy 6 (100%) 3,226 (0–9*10
22), 0.73
ALT >60 U/l 39 (69%) 2.37 (0.78–7.26), 0.13
Creatinine >130 μmol/l 74 (45%) 0.40 (0.20–0.83), 0.01
Age >65 years 52 (46%) 0.69 (0.33–1.45), 0.32
AST >80 U/l 28 (64%) 1.09 (0.33–3.68), 0.88
UTI
Empiric (n=72) Age >65 years 43 (16%) 0.71 (0.20–2.50), 0.59
Active malignancy 8 (0%) 0 (0–6*10
24), 0.80
Temperature >38.5°C 30 (13%) 0.29 (0.07–1.18), 0.08
Leukocytes <4 or >12*10
9/l 25 (32%) 2.95 (0.79–11), 0.11
Culture-driven
(n=119)
Predisposing illness 49 (43%) 0.61 (0.27–1.37), 0.23
Temperature >38.5°C 18 (67%) 1.71 (0.55–5.27), 0.35
Leukocytes 4< or >12*10
9/l 22 (64%) 1.90 (0.66–5.46), 0.24
AST >80 U/l 5 (100%) 1,189 (0–4*10
16), 0.66
LRTI
Empiric (n=422) Age >65 years 217 (87%) 1.56 (0.89–2.73), 0.12
Active malignancy 49 (96%) 4.40 (1.03–18.83), 0.045
CVA 39 (77%) 0.50 (0.21–1.16), 0.11
Diabetes 80 (89%) 1.67 (0.78–3.58), 0.19
Predisposing illness 35 (91%) 1.65 (0.48–5.70), 0.43
Culture-driven
(n=204)
Alcohol/intravenous drug abuse 15 (40%) 0.32 (0.10–0.96), 0.04
Chronic hepatic
insufficiency
3 (33%) 0.73 (0.06–9.66), 0.81
Urinary catheter 36 (78%) 1.73 (0.72–4.15), 0.22
Creatinine >130 μmol/l 35 (49%) 0.37 (0.17–0.81), 0.01
Table 3 Comparison of antimicrobial prescriptions with guideline recommendations and impact of culture results (UTI urinary tract
infection, LRTI lower respiratory tract infection)
Empiric therapy N (% compliant) Culture-driven therapy N (% compliant)
a Odds ratiodoc/emp (95% CI)
b
Overall Initial Follow-up
Sepsis 166 (52%) 142 (54%) 32 (53%) 110 (55%) 1.07 (0.69–1.69) p=0.89
c
UTI 72 (22%) 119 (50%) 69 (45%) 50 (58%) 3.56 (1.84–6.90) p=0.16
c
LRTI 422 (84%) 204 (68%) 60 (73%) 144 (65%) 0.39 (0.26–0.58) p=0.26
c
aCulture-driven therapy is divided into prescriptions that were not preceded by an antimicrobial prescription (initial) and those that were
preceded by another antimicrobial prescription (follow-up). (See Methods section)
bThe odds ratios and 95% confidence intervals are given of the impact of the availability of culture results on prescribing compliance
compared with prescribing compliance for empiric therapy
cPearson chi-square
301scribing in patients with sepsis and LRTI. Age, comorbid
disease, and disease severity had no impact on empiric or
culture-driven therapy of UTI.
How rational is noncompliant therapy?
In the majority of noncompliant prescriptions, therapy had
a similar safety profile and comparable efficacy as
guideline-recommended therapy, but excessively broad-
spectrum agents were used for the expected or isolated
pathogens. Approximately a third of all prescriptions
(sepsis 41%, UTI 40%, LRTI 27%) were too broad for
empiric therapy and roughly two-thirds for culture-driven
therapy (sepsis 65%, UTI 71%, LRTI 59%) (Table 5). In
11–14% the prescribed antimicrobials assessed as non-
compliant were in fact comparable to guideline-recom-
mended agents on all three criteria. In 10 (13%)
prescriptions for sepsis and in 22 (one-third) prescriptions
for LRTI, the noncompliant empiric therapy hadtoo narrow
a spectrum, but it had a safety profile similar to guideline-
recommended therapy. In cases of sepsis, co-amoxiclav
was prescribed eight times, mainly for catheter-related
urosepsis, instead of the guideline-recommended amoxi-
cillin with either tobramycin or ciprofloxacin. In cases of
LRTI, national and professional group guidelines for CAP
were followed (for instance, amoxicillin was prescribed
instead of the recommended co-amoxiclav for CAP), but
those recommendations were not appropriate according to
the local guidelines for CAP.
Discussion
The hypothesis that patient and disease characteristics
were relevant for prescribing in line with recommenda-
tions could be confirmed only for a limited number of
characteristics; predisposing illnesses and active malig-
nancies were associated with more compliant prescribing,
whereas alcohol/intravenous drug abuse and serum creat-
inine levels >130 μmol/l were associated with less
compliant prescribing. In our study, compliance with
guideline recommendations differed considerably between
and within the groups of infections studied. Compliance
was much higher for LRTI than for sepsis and UTI.
Noncompliant prescribing was mainly too broad com-
pared with guideline-recommended therapy and seldom
too narrow. Availability of culture results led to more
targeted drug choices—that is, to use of narrower-
spectrum agents—only for UTI.
The fact that few relevant patient and disease character-
istics could be identified may in part be due to physicians’
lack of awareness of disease severity criteria in the
guideline or to incomplete documentation, as found
elsewhere [23]. Patients were to a large extent treated
with unduly broad-spectrum therapy with limited con-
sideration of local bacterial resistance patterns. Such
defensive behaviour is also described as occurring else-
where [8, 14, 23, 24]. When available culture results rec-
ommended the use of more targeted narrow-spectrum
therapy the advice was not followed. The recommended
“streamlining” approach of narrowing initial broad-spec-
Table 5 Noncompliant antimicrobial therapy (UTI urinary tract infection, LRTI lower respiratory tract infection)
Prescribed antimicrobials compared
with guideline-recommended therapy
a
Sepsis UTI LRTI
Empiric therapy
Spectrum too broad only 32 (41%) 22 (40%) 18 (27%)
Less efficacious because of covering
a too-narrow range of pathogens
10 (13%) – 22 (33%)
Similar (for efficacy, safety,
and bacterial spectrum criteria)
9 (11%) 7 (13%) 10 (13%)
Spectrum too broad with a less favourable safety profile 8 (10%) 4 (7%) 3 (5%)
Spectrum too broad without adequately
covering the expected pathogens for a specific
indication but with a more favourable safety profile
3 (4%) 6 (11%) –
Spectrum too broad with a more favourable safety profile 2 (3%) 6 (11%) –
Other 14 (18%) 11 (20%) 13 (20%)
Total 79 56 66
Culture-driven therapy
Spectrum too broad only 42 (65%) 42 (71%) 39 (59%)
Similar (for efficacy, safety, and bacterial spectrum criteria) 7 (11%) 8 (14%) 11 (17%)
Other 16 (24%) 9 (15%) 16 (24%)
Total 65 59 66
aRationale of noncompliant antimicrobials is compared with guideline-recommended antimicrobials on three criteria: safety, efficacy,
and bacterial spectrum covered. They can be more, less, or equally safe (adverse event profile/intrinsic toxicity) or effective (covering
expected or isolated pathogens), and their spectrum can cover more, less, or a similar number of pathogens (whether relevant for the
infection or not) than the guideline-recommended agent. In total, 27 categories (3*3*3) are possible, of which those are shown that
describe at least 10% of noncompliant prescriptions within one infection
302trum therapy to therapy directed at the isolated pathogen’s
sensitivity was not practised [2, 19, 25, 26]. Resident phy-
sicians in our hospital preferred to stay with their initial
therapeutic choices because of the adage, “Never change a
winning team” [27]. Defensive behaviour may in some
cases be driven by fear of high mortality rates and the fact
that inadequate initial bacterial coverage has been
correlated with increased mortality [28, 29].
Defensive behaviour might also explain less compliance
in the few alcohol/ intravenous drug abusers. Broader-
spectrum agents with additional anaerobic coverage were
prescribed, which may be prompted by physicians’ having
in the back of their minds the increased risk of aspiration
pneumonia in these patients. Similarly, more compliance
for patients with predisposing illnesses seemed also driven
by defensive behaviour. In these cases, physicians were
possibly more cautious and therefore more inclined to
check the guidelines carefully when treating patients with
acute complications of previous clinical interventions.
In cases of LRTI, defensive behaviour coincided with
the guideline-recommended broad-spectrum empiric ther-
apy with co-amoxiclav. However, therapy was not often
streamlined after culture results became available. This
explains the steep decline in compliance in culture-driven
therapy. A typical example was the treatment of a patient
with CAP who was initially treated empirically with co-
amoxiclav. Here, when test results become available, the
guidelines suggest narrowing therapy down to penicillin G
or amoxicillin for streptococci and flucloxacillin for S.
aureus infections [19, 30], as these narrow-spectrum
antibiotics still have, in the Dutch setting, good efficacy
against these pathogens [25, 31].
Similarly, in cases of alcohol or intravenous drug abuse,
culture-driven therapy for LRTI was not targeted to the
isolated pathogens. Although some exotic pathogens were
isolated, such as Serratia liquefaciens and Hafnia alvei,
mostly S. pneumoniae and S. aureus with normal antibiotic
sensitivity were found. Thus, no compelling reasons can be
given why culture-driven therapy should not be targeted to
the reported bacterial sensitivity in this group of patients.
Physicians in our hospital who were reluctant to
prescribe tobramycin possibly feared its nephrotoxic side
effects even though it was recommended in the guideline
[27]. In sepsis cases, this led to prescribing agents of too
narrow a spectrum—mainly co-amoxiclav—indicating that
defensive considerations are not the single driving force in
prescribing behaviour. In line with this finding, elevated
serum creatinine (>130 μmol/l) levels were associated with
less compliance for culture-driven therapy of sepsis and
LRTI. Physicians in these cases seemed more inclined to
choose nonrecommended antibiotics than to make dose
adjustments for recommended antibiotics (for example, for
tobramycin). One could argue that this reluctance to use
aminoglycosides is reasonable in view of their toxicity and
often subsequent need for dose adjustments. The guideline,
however, emphasises the effectiveness of aminoglycosides
for seriously ill patients because of their rapid bactericidic
action and widening of the bacterial spectrum when added
to betalactams [32]. Therapeutic drug monitoring is rec-
ommended to maintain appropriate and safe drug levels
and is generally performed in aminoglycoside therapy in
our hospital. In addition, resistance to aminoglycosides is
very low in the Netherlands (2–7%) [33].
Empiric therapy of LRTI was also too narrow in a third
of the cases. This may be due to misperceptions about the
pathogens present in the local population, which differs
from the general population because of the overrepresenta-
tion of diabetics, patients with chronic obstructive pulmo-
nary disease (COPD), and alcoholics. In an earlier study we
found that physicians, when asked to “treat” a paper CAP
case, thought S. pneumoniae was the most likely causative
pathogen [27]. Therefore, they would consider therapy
with amoxicillin or even benzylpenicillin appropriate [27],
as recommended in national Dutch and professional
pulmonology society guidelines for CAP [30, 34]. How-
ever, the guideline recommends co-amoxiclav because
Haemophilus influenzae and Klebsiella pneumoniae are
frequently isolated in these patients in our hospital. This
illustrates the need to stress to physicians that local
guidelines sometimes differ from national guidelines
[35]. The long duration of stay of patients with LRTI
may be explained by the overall case-mix, in which
patients with considerable comorbidity, such as COPD or
cystic fibrosis or in whom Pseudomonas was cultured,
were overrepresented.
In cases of UTI, physicians seemed to prefer ciproflox-
acin despite the growing evidence of resistance associated
with inappropriate and abundant use of fluoroquinolones
[25, 36, 37]. Routine decision-making by physicians may
play a role here. Such routine-like prescribing behaviour
has been reported in primary care [38] and was mentioned
by physicians in an earlier study [27]. In the Netherlands,
use of co-trimoxazole for treating male patients with lower
UTIs, as recommended by the guideline, is quite acceptable
[39]. Both co-trimoxazole and ciprofloxacin have good
tissue-penetrating properties, which is important in these
patients, in whom the prostrate is often affected. Cipro-
floxacin is then reserved for those cases in which isolated
pathogens are resistant to co-trimoxazole. This choice may
be explained by the concern in this guideline to prevent
increasing levels of ciprofloxacin resistance.
Low compliance with recommendations for sepsis, UTI,
and LRTI may be explained by a perceived lack of quality
of the guidelines. As discussed, hospital guideline
recommendations were developed in relation to epidemio-
logical data of isolated pathogens and antimicrobial
sensitivity patterns in the hospital catchment’s population,
and they may therefore differ from international and
national recommendations. This approach is considered
good practice for antimicrobial guidelines [26, 40, 41].
This implies that guideline developers have to invest more
effort in communicating to prescribers why local recom-
mendations may differ, particularly in view of specialists’
reluctance to use local guidelines when international or
professional group guidelines exist [35]. The need for local
adaptations may be higher in a university hospital setting,
where the patient population is more likely to differ from
the general population.
303Limitations of this study are that only those aspects of
care that were reported in the medical dossier could be
considered and that proxies for disease severity were used
instead of validated disease severity score systems such as
PSI or APACHE or a full clinical picture that included
regular visual inspection of a patient’s progress. Another
limitation is that for UTI, the number of antimicrobials
prescribed was limited, which reduced the study’s
statistical power. This lack of statistical power may have
prevented the criterion of an elevated temperature becom-
ing a significant determinant of noncompliant prescribing.
In conclusion, patient characteristics had only a limited
impact on compliant prescribing. What seemed to be more
important were the preference for some overly broad-
spectrum drugs, driven by defensive behaviour and a
dislike for other agents (for example, fear of possible toxic
drug effects, such as nephrotoxicity from aminoglyco-
sides), and for narrow-spectrum drugs due to additional
work involved in streamlining therapy and perceived risk
of reduced efficacy. Additionally, awareness of individual
and epidemiological culture results and appropriate follow-
up need further attention. Efforts to improve compliance
with the guidelines should target specific antibiotic drug
choices rather than specific patient groups, stressing the
full armamentarium available besides guidelines, such as
therapeutic drug monitoring, bacterial lab facilities and
pro-active support of clinical microbiology and hospital
pharmacy staff. The results stress the importance of
involving the prescribers in the guidelines development
and implementation, providing them with the opportunity
to voice their concerns and views on the relation with
(inter)national guidelines.
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Appendix
Hospital guidelines, University Medical Center
Groningen [19]
The guideline consists of 17 chapters on antimicrobial
therapy and eight chapters on antimicrobial prophylaxis.
Additional chapters give recommendations on antimicro-
bial use for pregnant and breastfeeding women and for
renal- and hepatic-impaired patients, and antibacterial
sensitivity patterns of isolated pathogens in the hospital.
The guideline also gives general recommendations on
when and how to take appropriate bacterial culture samples
and how to streamline therapy. Literature references are
given, on which the guideline recommendations are based.
As an example for the three most common type of
infections, guideline-recommended agents for empiric
therapy are given below. The guideline also gives
recommendations on dosing, administration route, and
duration of therapy (not shown).
Type of infection Recommended drug choice
Urinary tract infection (UTI)
Lower UTI
-Uncomplicated Nitrofurantoin, trimethoprim
(or norfloxacin)
-Male Co-trimoxazole
-Catheter in situ (with fever) Amoxicillin + tobramycin
Acute pyelonephritis Cefuroxime + tobramycin, or
ciprofloxacin
Sepsis
-Urosepsis, no catheter Cefuroxime or tobramycin
-Urosepsis, catheter in situ Amoxicillin + (ciprofloxacin
or tobramycin)
-Hospital-acquired pneumonia Cefuroxime + tobramycin
-Abdominal, unknown location Amoxicillin + tobramycin+
metronidazole
-Abdominal, bile duct Piperacillin + tobramycin
Lower respiratory tract infections
Community-acquired pneumonia
(suspected Legionella)
Co-amoxiclav
(+ erythromycin)
Hospital-acquired pneumonia, severe
or with additional risk factors
Cefuroxime + tobramycin, or
ceftazidime
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